MEDP in the 13F filings
Medpace HLDGS Inc · CUSIP 58506Q109
- Quarter end
- 31 Mar 2024
- the date the book describes
- Filed
- 15 May 2024
- latest of these filings; the earliest 10 May 2024
- Managers listing it
- 17
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q4 2023 and Q1 2024; 14 listed it in both
- Shares listed
- 2,943,527
- combined, among listed positions
- Reported value
- $1.2bn
- combined, at the quarter end
Among the 93 comparable managers: 9 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing MEDP in Q1 2024
17 of 17 holders
Largest increases and reductions, by shares
Increases
- D. E. Shaw & Co.existing position · 372,079 shares now+140,519
- Renaissance Technologies LLCexisting position · 320,788 shares now+69,400
- Arrowstreet Capital LPexisting position · 250,998 shares now+56,899
- Voloridge Investment Management LLCexisting position · 168,547 shares now+16,041
- Caxton Associates LLPexisting position · 3,967 shares now+2,840
Reductions
- Two Sigma Investments LPexisting position · 77,500 shares now-38,772
- Man Group PLCexisting position · 136,028 shares now-34,917
- Acadian Asset Management LLCexisting position · 23,945 shares now-31,514
- Two Sigma Advisers LPexisting position · 150,800 shares now-7,200
- AQR Capital Management LLCexisting position · 191,393 shares now-4,004
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2017 | 2 | $21m | n.a. | n.a. |
| Q2 2017 | 1 | $14m | n.a. | n.a. |
| Q3 2017 | 1 | $19m | n.a. | n.a. |
| Q4 2017 | 1 | $23m | n.a. | n.a. |
| Q1 2018 | 3 | $37m | n.a. | n.a. |
| Q2 2018 | 4 | $59m | n.a. | n.a. |
| Q3 2018 | 14 | $247m | n.a. | n.a. |
| Q4 2018 | 6 | $119m | n.a. | n.a. |
| Q1 2019 | 4 | $100m | n.a. | n.a. |
| Q2 2019 | 4 | $117m | n.a. | n.a. |
| Q3 2019 | 6 | $140m | n.a. | n.a. |
| Q4 2019 | 5 | $122m | n.a. | n.a. |
| Q1 2020 | 7 | $144m | n.a. | n.a. |
| Q2 2020 | 8 | $173m | n.a. | n.a. |
| Q3 2020 | 12 | $218m | n.a. | n.a. |
| Q4 2020 | 8 | $187m | n.a. | n.a. |
| Q1 2021 | 9 | $153m | n.a. | n.a. |
| Q2 2021 | 8 | $156m | n.a. | n.a. |
| Q3 2021 | 11 | $413m | n.a. | n.a. |
| Q4 2021 | 12 | $668m | n.a. | n.a. |
| Q1 2022 | 6 | $107m | n.a. | n.a. |
| Q2 2022 | 5 | $97m | n.a. | n.a. |
| Q3 2022 | 3 | $59m | n.a. | n.a. |
| Q4 2022 | 10 | $269m | n.a. | n.a. |
| Q1 2023 | 14 | $275m | n.a. | n.a. |
| Q2 2023 | 17 | $468m | n.a. | n.a. |
| Q3 2023 | 15 | $378m | n.a. | n.a. |
| Q4 2023 | 14 | $501m | 8 | 7 |
| Q1 2024 | 17 | $1.2bn | 9 | 8 |
| Q2 2024 | 18 | $1.3bn | 9 | 9 |
| Q3 2024 | 15 | $918m | 9 | 6 |
| Q4 2024 | 15 | $1.2bn | 9 | 6 |
| Q1 2025 | 12 | $986m | 11 | 1 |
| Q2 2025 | 14 | $1.2bn | 12 | 3 |
| Q3 2025 | 17 | $1.9bn | 9 | 8 |
| Q4 2025 | 14 | $2.1bn | 14 | 21 |
| Q1 2026 | 12 | $1.8bn | 12 | 21 |
| Q2 2026 | 9 | $2.7bn | 8 | 21 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MEDP and LLY →MEDP and JNJ →MEDP and VRTX →Choose a stock to compare with MEDP →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MEDP, latest filings →Back to the 13F Explorer →